Differential p53 engagement in response to oxidative and oncogenic stresses in fanconi anemia mice

Cancer Research

Volumn 68, Issue 23, 2008, Pages 9693-9702

  Rani, Reena ^a   Li, Jie ^a   Pang, Qishen ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOPROTEIN; PROTEIN P19 ARF; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; FANCA GENE; FANCONI ANEMIA; GENE; GENE ACTIVATION; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE; ONCOGENE H RAS; ONCOGENE RAS; ONCOGENIC STRESS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FAMILY; RETROVIRUS; SIGNAL TRANSDUCTION; TRP53 GENE; WILD TYPE;

ANIMALS; BONE MARROW CELLS; CELL DIVISION; DNA DAMAGE; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN; FIBROBLASTS; G2 PHASE; HUMANS; HYDROGEN PEROXIDE; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDANTS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 57149085487     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1790     Document Type: Article

References (52)

1. Bagby GC. Genetic basis of Fanconi anemia. Curr Opin Hematol 2003;10:68-76.
2. Collins N, Kupfer GM. Molecular pathogenesis of Fanconi anemia. Int J Hematol 2005;82:176-83.
3. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005;19:2925-40.
4. Timmers, C, Taniguchi T, Hejna J, et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 2001;7:241-8.
5. Strathdee CA, Gavish H, Shannon WR, Buchwald M. Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 1992;356:763-7.
6. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, et al. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet 1996;14:320-3.
7. de Winter JP, Waisfisz Q, Rooimans MA, et al. The Fanconi anaemia group G gene FANCG is identical with XRCC9. Nat Genet 1998;20:281-3.
8. de Winter JP, Rooimans MA, van Der WL, et al. The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet 2000;24:15-6.
9. de Winter JP, Leveille F, van Berkel CG, et al. Isolation of a cDNA representing the Fanconi anemia complementation group E gene. Am J Hum Genet 2000;67:1306-8.
10. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
11. Meetei AR, de Winter JP, Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 2003;35:165-70.
12. Meetei AR, Levitus M, Xue Y, et al. X-linked inheritance of Fanconi anemia complementation group B. Nat Genet 2004;36:1219-24.
13. Meetei AR, Medhurst AL, Ling C, et al. A human ortholog of archael DNA repair protein HEF is defective in Fanconi anemia complementation group M. Nat Genet 2005;37:958-63.
14. Levran O, Attwooll C, Henry RT, et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 2005;37:931-3.
15. Levitus M, Waisfisz Q, Godthelp BC, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 2005;37:934-5.
16. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 2006;39:159-61.
17. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FAN and predispose to childhood cancer. Nat Genet 2006;39:162-4.
18. Smogorzewska A, Matsuoka S, Vinciguerra P, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007;129:1-13.
19. Pagano G, Degan P, d'Ischia M, et al. Oxidative stress as a multiple effector in Fanconi anaemia clinical phenotype. Eur J Haematol 2005;75:93-100.
20. Kruyt FA, Hoshino T, Liu JM, Joseph P, Jaiswal AK, Youssoufian H. Abnormal microsomal detoxification implicated in Fanconi anemia group C by interaction of the FAC protein with NADPH cytochrome P450 reductase. Blood 1998;92:3050-6.
21. Cumming RC, Lightfoot J, Beard K, Youssoufian H, O'Brien PJ, Buchwald M. Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat Med 2001;7:814-20.
22. Hadjur S, Ung K, Wadsworth L, et al. Defective hematopoiesis and hepatic steatosis in mice with combined deficiencies of the genes encoding Fancc and Cu/Zn superoxide dismutase. Blood 2001;98:1003-11.
23. Futaki M, Igarashi T, Watanabe S, et al. The FANCG Fanconi anemia protein interacts with CYP2E1: possible role in protection against oxidative DNA damage. Carcinogenesis 2002;23:67-72.
24. Mukhopadhyay SS, Leung KS, Hicks MJ, Hastings PJ, Youssoufian H, Plon SE. Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia. J Cell Biol 2006;175:225-35.
25. Saadatzadeh MR, Bijangi-Vishehsaraei K, Hong P, Bergmann H, Haneline LS. Oxidant hypersensitivity of Fanconi anemia type C-deficient cells is dependent on a redox-regulated apoptotic pathway. J Biol Chem 2004;279:16805-12.
26. Park SJ, Ciccone SL, Beck BD, Hwang B, Freie B, Clapp DW, Lee SH. Oxidative stress/damage induces multimerization and interaction of Fanconi anemia proteins. J Biol Chem 2004;279:30053-9.
27. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990;348:331-3.
28. Elson A, Deng C, Campos-Torres J, Donehower LA, Leder P. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene 1995;11:181-90.
29. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998;12:2973-83.
30. Lohrum MA, Vousden KH. Regulation and activation of p53 and its family members. Cell Death Differ 1999;6:1162-8.
31. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci 2001;114:4139-40.
32. Kutler DI, Wreesmann VB, Goberdhan A, et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003;95:1718-21.
33. Lowy DR, Gillison ML. A new link between Fanconi anemia and human papillomavirus-associated malignancies. J Natl Cancer Inst 2003;95:1648-50.
34. Jonkers J, Meuwissen R, van der Gulden H, et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29:418-25.
35. +/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice. Cancer Res 2005;65:85-91.
36. Freie B, Li X, Ciccone SL, et al. Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood 2003;102:4146-52.
37. 2 checkpoint. J Biol Chem 2004;279:50986-93.
38. Liu TX, Howlett NG, Deng M, et al. Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis. Dev Cell 2003;5:903-14.
39. Satyanarayana A, Rudolph KL. p16 and ARF: activation of teenage proteins in old age. J Clin Invest 2004;114:1237-40.
40. Lander HM, Milbank AJ, Tauras JM, et al. Redox regulation of cell signaling. Nature 1996;381:380-1.
41. Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281:1674-7.
42. Celeste A, Difilippantonio S, Difilippantonio MJ, et al. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 2003;114:371-83.
43. Friedlander P, Haupt Y, Prives C, Oren M. Mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 1996;16:4961-71.
44. Ferbeyre G, de Stanchina E, Lin AW, et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 2002;22:3497-508.
45. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
46. Scolnick DM, Chehab NH, Stavridi ES, et al. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res 1997;57:3693-6.
47. Zhang X, Sejas DP, Qiu Y, Williams DA, Pang Q. Inflammatory ROS promote and cooperate with Fanconi anemia mutation for hematopoietic senescence. J Cell Sci 2007;120:1572-83.
48. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
49. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003;10:431-42.
50. Levine AJ, Finlay CA, Hinds PW. P53 is a tumor suppressor gene. Cell 2004;116:S67-70.
51. Ianzini F, Bertoldo A, Kosmacek EA, Phillips SL, Mackey MA. Lack of p53 function promotes radiation-induced mitotic catastrophe in mouse embryonic fibroblast cells. Cancer Cell Int 2006;6:11-8.
52. Park SS, Eom YW, Choi KS. Cdc2 and Cdk2 play critical roles in low dose doxorubicin-induced cell death through mitotic catastrophe but not in high dose doxorubicin-induced apoptosis. Biochem Biophys Res Commun 2005;334:1014-21.